• To allow for comparison between the OL and DB phases, which were of different length, the average cost per person-year was estimated as the ratio between the cumulative cost in a treatment group and the total person-years accumulated in a treatment group during the given period in that group
The weighted method with cost history by Lin et al 10 was used to estimate the average cost and average cost difference between treatment groups during the DB phase; 95% CIs were calculated using the bootstrap method for the differences in cost between treatment groups
• To calculate Lin's weighted averages, the study duration was partitioned into equal time intervals. The average cost of those patients who were alive and did not relapse at the beginning of the interval was multiplied by the survival probability at the beginning of the interval. The average total cost for a treatment group was obtained by summing the weighted average costs for each interval
RESULTS
• Efficacy and safety results were presented in Berwaerts et al 11 • A total of 506 patients with schizophrenia entered the transition phase, and 305 patients who completed both the transition and maintenance phases were randomized to treatment with PP3M (n = 160) and placebo (n = 145) in the DB phase. Of the 305 patients in the ITT (DB) population, 35 (11%) patients discontinued from the DB phase (17 [6%] due to patient withdrawal of consent). Of the 305 patients, 270 (89%) completed the study, of whom 56 (18%) had a relapse event and 214 (70%) were ongoing in the DB phase at the time the study was stopped
• Table 2 presents the demographic characteristics of the ITT (DB) population. The treatment groups appeared similar with respect to the baseline characteristics, with patients predominantly male (n = 228, 75%), white (n=195, 64%), not Hispanic or Latino (n = 250, 82%), and 37.8 (standard deviation [SD] = 11.01) years old 
HRU Analysis
• The incidence rate of hospitalizations due to psychiatric and social reasons at baseline OL appeared similar in patients receiving placebo and those receiving PP3M (0.51 and 0.58 hospitalizations per person-year, respectively), decreased to similar values at baseline DB (0.12 and 0.14 hospitalizations per person-year, respectively), and increased during the DB period to 0.45 for patients receiving placebo while remaining similar at 0.15 for patients receiving PP3M (Table 3) • When hospitalizations due to social and psychiatric reasons occurred during the DB phase, the incidence rate was higher in patients receiving placebo than in those receiving PP3M at weeks 41 and 53 and at EOS during the DB phase (Figure 1) • The incidence rate of hospitalizations due to psychiatric reasons only at baseline OL was numerically higher for patients receiving placebo and PP3M (0.46 and 0.56 hospitalizations per person-year, respectively), decreased to similar values at baseline DB (0.0 and 0.03 hospitalizations per person-year, respectively), and increased during the DB phase to 0.19 for patients receiving placebo while remaining similar at 0.04 for patients receiving PP3M. A similar pattern was observed for all subgroups (Table 3) • The incidence rate of hospitalization due to psychiatric reasons only was zero at all DB phase scheduled visits, and it was higher in patients receiving placebo than in those receiving PP3M at EOS during the DB phase (Figure 2) • The overall incidence rates of ER visits due to different reasons were generally low (<0.1) and comparable between treatment groups (data not shown)
• Overall, the incidence rate of day clinic visits due to social and psychiatric reasons and to psychiatric reasons alone was higher in patients receiving PP3M than those receiving placebo; the incidence rate was lower during the DB phase than during the other two periods (data not shown)
• Overall, the incidence rate for consultations with psychologists, psychiatric nurses, and therapists outside of trial visits was relatively low and appeared similar between treatment arms during the study. Consultations occurred mostly in the United States. The incidence rate for the other health professional visits was generally higher at baseline OL than baseline DB or DB phase, and there was no apparent trend (data not shown) • Nonadherence to oral antipsychotic therapy is common in schizophrenia and can lead to relapse (including rehospitalization), a common and major problem for patients with schizophrenia. 2 Long-acting antipsychotic treatments can positively influence medication adherence due to their less frequent dosing regimens 3 • A new formulation of paliperidone palmitate with a 3-month injection (PP3M) was studied by Janssen in clinical trial PSY-3012
OBJECTIVE
• Compare health resource utilization (HRU), collected using the Healthcare Resource Use Questionnaire (HRUQ), 4 and average total and major resource use costs between PP3M and placebo
METHODS

Data
• Clinical trial PSY-3012 was a randomized, multicenter, double-blind (DB), parallel-group, relapse-prevention study of PP3M; the main objective was to demonstrate efficacy (ie, delay of the time to first occurrence of relapse of schizophrenia symptoms) and safety of PP3M
• The study consisted of four phases: (1) a screening phase (up to 3 weeks); (2) a 17-week flexible-dose, open-label (OL) transition phase; (3) a 12-week fixed-dose, OL maintenance phase; and (4) a randomized, DB, fixed-dose, placebo-controlled relapse-prevention variable duration phase (referred to as the DB phase)
• The HRUQ was used to collect HRU data at various visits throughout PSY-3012: day 1 (baseline OL) and week 17 during OL phase; week 29 (baseline DB), week 41, and every 12 weeks afterward until the end of the study during the DB phase; and an end-of-study (EOS) assessment
End Points
• The following cost variables were derived based on collected HRU data only:
• Major cost categories
• Hospitalizations (≥1 night stay) and emergency room (ER) visits without a hospitalization
• Day or night clinic stays (<24-hour stay per day)
• Outpatient treatment (ie, psychiatrist or neurologist, psychologist, psychiatric nurse, general practitioner, social worker, therapist, and other), excluding trial visits
• Total HRU cost (ie, total cost of the major three categories)
• Total mental health-related HRU cost (ie, total cost of hospitalizations, ER visits, and day clinic visits for management of relapse, other psychiatric reason, and social reasons and psychiatrist or neurologist, psychologist, psychiatric nurse, social worker, therapist, and other), excluding trial visits
• The following HRU characteristics were used for unit cost derivation and analysis:
• 
Unit Costs
• HRU was costed in US dollars using the unit costs from the Paliperidone palmitate Research In Demonstrating Effectiveness (PRIDE) cost matrix, which provides Medicaid-based claims cost estimates, by multiplying the quantity of resource used by its corresponding unit cost. 5 Not all unit costs were directly available in the PRIDE cost matrix as categories with psychiatric reason for hospitalization or ER visit and type of hospital were not reported
• The unit costs for those resources in the PSY-3012 trial that were available in the PRIDE cost matrix were utilized and inflated to 2014 US dollars
• The unit cost for resources that were not directly available in the PRIDE cost matrix was estimated by using a similarly defined resource category in the PRIDE cost matrix and then adjusting based on weights and cost ratios obtained from online query systems of HCUPnet (for hospitalizations) and the Medical Expenditure Panel Survey (MEPS) (for ER visits) to estimate costs for reason of visit and hospital type. All costs were inflated to 2014 US dollars
• Table 1 presents the unit cost matrix for the resources that were included Any outpatient visit that was not involving a general practitioner, psychiatrist, neurologist, psychologist, psychiatric nurse, social worker, or therapist (eg, psycho-, physio-, occupational) was categorized as "other," and a single average cost was applied.
c Estimated using a similarly defined resource category in the PRIDE cost matrix and adjusting the cost to reflect 2014 US prices based on weights and cost ratios obtained from the online query systems of HCUPnet (for hospitalizations) and the MEPS (for ER visits). Cost were inflated to 2014 US dollars. 
Statistical Methods
• The analysis population used in this project was the intent-to-treat (ITT) DB analysis set. This analysis set included all patients who were randomly assigned to treatment during the DB phase and received at least one dose of DB study drug
• No P values or confidence intervals (CIs) were provided for the descriptive analyses (ie, incidence rate, average cost per person-year)
HRU Analysis
• Incidence rate per person-year (ie, incidence density) was estimated for count variables (ie, number of hospitalizations, ER visits, day clinic services, night clinic services, and outpatient treatment) as the ratio of the resources used by all patients in a treatment group to the sum of time intervals during which each of those patients accumulated the resources. 9 This rate was estimated over the entire DB phase 
Cost Analysis
• Hospitalizations and ER visits represent the majority of the total and mental health-related HRU costs
• During the OL phase, the mean per person-year costs were comparable between the patients randomized to the two treatment groups
• During the DB phase, the total and mental health-related HRU costs increased in the placebo treatment group and decreased in the PP3M group due to the increase in placebo and decrease in PP3M hospitalization and ER visit costs, respectively ( Table 4) • After accounting for different length of study and censoring during the DB phase by using Lin's weighted method, the total HRU costs (-$1,469; 95% CI, -$2,817 to -$230), mental health-related costs (-$1,400; 95% CI, -$2,775 to -$191), and hospitalization and ER visit costs (-$1,582; 95% CI, -$2,943 to -$359) were significantly lower in the PP3M treatment group than in placebo treatment group ( Mean cost difference (95% CI)
US $
Note: Negative mean cost indicates lower cost for PP3M. Significant differences are indicated by 95% CIs that do not contain zero costs.
LIMITATIONS
• Patients in the trial were not followed beyond one relapse, so results reported do not reflect resource use of subsequent relapses
• The visual comparison of incidence rates and mean per person-year should be interpreted with caution, because no formal statistical comparisons were made
• To estimate the costs in the United States, Medicaid unit costs were applied to resources collected from an international trial, which could underestimate or overestimate the costs due to differences in health care systems across countries
• The assumption that censoring happens at the end of the interval, required by the Lin's weighted method, is not usually met in practice; therefore, the mean estimates might be biased downward
CONCLUSIONS
• With a few exceptions, incidence rates of resources at baseline OL were higher than the incidence rates during the study, and they were low for most resources
• Incidence rates of most resources were comparable between placebo and PP3M at baseline DB, and then increased for placebo and appeared to remain similar for PP3M during the DB phase
• Hospitalization and ER visit costs represent the majority of the total and mental health-related HRU costs
• During the OL phase, total and mental health-related HRU costs appeared similar for both treatment groups, but from the OL phase to the DB phase, costs increased considerably in the placebo group and decreased in the PP3M group
• Total HRU and mental health-related costs as well as hospitalization and ER visit costs were significantly lower in the PP3M group than in the placebo group after patients were stabilized on PP1M in the OL transition phase, given one dose of PP3M during the OL maintenance phase, and then randomized to PP3M versus placebo in the DB phase
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PMH27 BACKGROUND
• Schizophrenia is a chronic mental health disorder that affects approximately 1.1% of the adult population in the United States 1
• Nonadherence to oral antipsychotic therapy is common in schizophrenia and can lead to relapse (including rehospitalization), a common and major problem for patients with schizophrenia. Long-acting antipsychotic treatments can positively influence medication adherence due to their less frequent dosing regimens 3 • A new formulation of paliperidone palmitate with a 3-month injection (PP3M) was studied by Janssen in clinical trial PSY-3012
OBJECTIVE
METHODS
Data
End Points
• Reason (ie, management of relapse, other psychiatric reason, social reason, and other medical reason) for hospitalizations, ER visits, and day clinic visits
• Type of hospital (ie, university, psychiatric/mental, general/regional, long-term care/rehabilitation facility, and other) for hospitalizations and day clinic visits
• Type of ward for hospitalizations only (ie, psychiatry, general/internal medicine, intensive care, surgery, and other)
Unit Costs
• Table 1 presents the unit cost matrix for the resources that were included Any outpatient visit that was not involving a general practitioner, psychiatrist, neurologist, psychologist, psychiatric nurse, social worker, or therapist (eg, psycho-, physio-, occupational) was categorized as "other," and a single average cost was applied. c Estimated using a similarly defined resource category in the PRIDE cost matrix and adjusting the cost to reflect 2014 US prices based on weights and cost ratios obtained from the online query systems of HCUPnet (for hospitalizations) and the MEPS (for ER visits). Cost were inflated to 2014 US dollars. 
Statistical Methods
HRU Analysis
• Incidence rate per person-year (ie, incidence density) was estimated for count variables (ie, number of hospitalizations, ER visits, day clinic services, night clinic services, and outpatient treatment) as the ratio of the resources used by all patients in a treatment group to the sum of time intervals during which each of those patients accumulated the resources. 9 This rate was estimated over the entire DB phase
Cost Analysis
into equal time intervals. The average cost of those patients who were alive and did not relapse at the beginning of the interval was multiplied by the survival probability at the beginning of the interval. The average total cost for a treatment group was obtained by summing the weighted average costs for each interval
RESULTS
HRU Analysis
• Overall, the incidence rate for consultations with psychologists, psychiatric nurses, and therapists outside of trial visits was relatively low and appeared similar between treatment arms during the study. Consultations occurred mostly in the United States. The incidence rate for the other health professional visits was generally higher at baseline OL than baseline DB or DB phase, and there was no apparent trend (data not shown) 
Cost Analysis
• During the DB phase, the total and mental health-related HRU costs increased in the placebo treatment group and decreased in the PP3M group due to the increase in placebo and decrease in PP3M hospitalization and ER visit costs, respectively ( Table 4) • After accounting for different length of study and censoring during the DB phase by using Lin's weighted method, the total HRU costs (-$1,469; 95% CI, -$2,817 to -$230), mental health-related costs (-$1,400; 95% CI, -$2,775 to -$191), and hospitalization and ER visit costs (-$1,582; 95% CI, -$2,943 to -$359) were significantly lower in the PP3M treatment group than in placebo treatment group (Table 5, Figure 3 ) Mean cost difference (95% CI)
US $
LIMITATIONS
